Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV CR845 (difelikefalin) in hemodialysis patients with moderate-to-severe pruritus
2018-004572-35Phase 3Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- May 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of difelikefalin in chronic kidney disease-associated pruritus (CKD-aP), sponsored by Cara Therapeutics, Inc. Primary endpoint: Safety Endpoints. Started May 2019; status: completed.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on 2018-004572-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004572-35.